Product Name :
Rift Valley fever phlebovirus Nucleocapsid Protein（RVFV-NP） Background :
Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that was first discovered in Kenya in 1930 and is now endemic throughout multiple African countries and the Arabian Peninsula. RVF virus primarily infects domestic livestock (sheep, goats, cattle) causing high rates of neonatal mortality and abortion, with human infection resulting in a wide variety of clinical outcomes, ranging from self-limiting febrile illness to life-threatening haemorrhagic diatheses, and miscarriage in pregnant women. Since its discovery, RVF has caused many outbreaks in Africa and the Arabian Peninsula with major impacts on human and animal health. However, options for the control of RVF outbreaks are limited by the lack of licensed human vaccines or therapeutics. Product :
Inclusion body;0.5mol Urea,PH=8 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Carrier:pET30a-RVFV-NP-His(C-term) Virus:Rift Valley fever virus strain MP-12 segment S, complete sequence Immunogen :
pathway :

• 
  Rift Valley fever phlebovirus Nucleocapsid Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.

Blocking peptide available as NCP0154P